« Back
Home /
CBP/p300-IN-8

CBP/p300-IN-8

Item no.	HY-136920-50mg
Manufacturer	MedChem Express
CASRN	2304416-91-7
Amount	50 mg
Quantity options	10 mg 50 mg 5 mg
Category	Oncology By Cell Type Carcinoma Hematology Leukemia Lymphoma Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Shawn E.R. Schiller, et al. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors. WO2019055877A1.
Smiles	O=C(N1[C@@H](C)CCC2=C1C=CC3=C2N=C(CC4=CC=CC=C4)N3[C@@H]5C[C@@H](C(O)=O)CCC5)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	2304416-91-7
Similar products	2304416-91-7
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Epigenetic Reader Domain
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	461.55
Product Description	CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC50=0.01-0.1 µΜ) and BRD4 (IC50=1-1000 µΜ) activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 200 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics
Isoform	BRD4
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-136920-50mg-safety-datasheet.pdf